Plasma and Cellular Forms of Fibronectin as Prognostic Markers in Sepsis

Table 1

Baseline characteristics of patients.

	Survivors	Nonsurvivors	Control	value
	APACHE-II score	19.0 (13.0-25.0)	26.0 (20.0-32.0)			<0.001^a
SOFA score	9.0 (6.0-11.0)	13.0 (10.0-15.0)		<0.001^a
Procalcitonin (ng/L)	2.9 (0.5-12.9)	13.1 (2.8-33.0)		0.009^a
C-reactive protein (mg/L)	169.0 (87.8-302.5)	178.6 (98.9-283.1)	1.2 (0.4-1.9)	1.00^a
				<0.001^b,c
White blood cells (10^3/μL)	15.0 (11.0-21.8)	15.1 (10.7-21.2)		0.875^a
Haemoglobin (g/dL)	10.2 (8.2-11.6)	9.5 (8.6-10.7)		0.945^a
Fibrinogen (g/L)	5.2 (4.1-6.5)	5.2 (2.9-5.7)		0.279^a
pFN (mg/L)	152.8 (114.5-164.2)	106.0 (63.7-149.4)	231.2 (191.2-273.2)	0.004^a
				<0.001^b,c
EDA-FN (mg/L)	6.7 (3.8-20.5)	9.4 (2.6-20.3)	1.4 (0.9-1.6)	1.00^a
				<0.001^b,c
ICU free days to day 28	18 (9–21)	20 (9–24)		0.103^a

APACHE II: Acute Physiology and Chronic Health Evaluation II; SOFA: Sequential Organ Failure Assessment; pFN: plasma fibronectin; EDA-FN: extra domain A fibronectin; ICU: intensive care unit. The comparison of continuous variables between two independent groups (nonsurvivors vs. survivors) was performed using the Mann-Whitney test. The comparison of continuous variables across three groups (nonsurvivors, survivors, control) was performed using the Kruskal-Wallis test, and a post hoc was used to compare subgroups. The value represents statistically significant differences calculated between the following groups: ^anonsurvivors vs. survivors, ^bnonsurvivors vs. control, ^csurvivors vs. control.